Sponsored Links
| IQ Therapeutics Completes Dosing Of Antibody Against Anthrax In Phase I Clinical Trial |
 |
 |
 |
| Medical News - Bio-terrorism | |||
|
IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF. The dosing has been completed successfully and doses up to 7... Read more: Bio-terrorism / Terrorism News From Medical News Today
|